Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from SSY Group ( (HK:2005) ).
SSY Group Limited has announced that its product, Lornoxicam, has received approval from the National Medical Products Administration of China for registration as a bulk drug. This development marks a significant step in the company’s product offerings, potentially enhancing its market position in the pharmaceutical industry by expanding its portfolio of pain management solutions.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company specializes in creating medications for pain management and other therapeutic areas, with a market focus on China.
YTD Price Performance: -10.70%
Technical Sentiment Signal: Buy
Current Market Cap: $1.13B
For an in-depth examination of 2005 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue